<SEC-DOCUMENT>0001209191-20-023799.txt : 20200407
<SEC-HEADER>0001209191-20-023799.hdr.sgml : 20200407
<ACCEPTANCE-DATETIME>20200407171951
ACCESSION NUMBER:		0001209191-20-023799
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20200403
FILED AS OF DATE:		20200407
DATE AS OF CHANGE:		20200407

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Basta Steven L
		CENTRAL INDEX KEY:			0001417397

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38356
		FILM NUMBER:		20780461

	MAIL ADDRESS:	
		STREET 1:		1875 S GRANT STREET SUITE 110
		CITY:			SAN MATEO
		STATE:			CA
		ZIP:			94402

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Menlo Therapeutics Inc.
		CENTRAL INDEX KEY:			0001566044
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				453757789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		800-775-7936

	MAIL ADDRESS:	
		STREET 1:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170728

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tigercat Pharma, Inc.
		DATE OF NAME CHANGE:	20130104
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2020-04-03</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001566044</issuerCik>
        <issuerName>Menlo Therapeutics Inc.</issuerName>
        <issuerTradingSymbol>MNLO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001417397</rptOwnerCik>
            <rptOwnerName>Basta Steven L</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>520 U.S. HIGHWAY 22, SUITE 204</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>BRIDGEWATER</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08807</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2020-04-03</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>14499</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>536537</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (&quot;Menlo&quot;) issued additional shares of its common stock pursuant to certain contingent stock rights (&quot;CSRs&quot;) issued in connection with the March 9, 2020 merger (the &quot;Merger&quot;) of Menlo and Foamix Pharmaceuticals Ltd. (&quot;Foamix&quot;), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the &quot;Final Exchange Ratio&quot;). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Mutya Harsch, attorney-in-fact for Steven Basta</signatureName>
        <signatureDate>2020-04-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
